TLDR
Peptide concentration describes how much peptide is present in a given volume of solution. For injectable preparations, it is commonly expressed as milligrams per milliliter, or mg/mL.
The basic relationship is:
Concentration = amount of peptide ÷ final volume
So a solution containing 10 mg of peptide per 1 mL has a concentration of 10 mg/mL.
Syringe markings are a separate measurement. On a U-100 insulin syringe, 100 markings correspond to 1 mL of volume, so 20 syringe units represent 0.20 mL. The number of milligrams in that 0.20 mL depends entirely on the concentration of the drug.
For example:
- 5 mg/mL × 0.20 mL = 1 mg
- 10 mg/mL × 0.20 mL = 2 mg
- 20 mg/mL × 0.20 mL = 4 mg
This is why saying someone injected “20 units” does not identify the drug dose unless the concentration is also known.
The distinction has caused real medication errors. FDA has documented patients receiving five to 20 times their intended dose of compounded semaglutide because of confusion among milligrams, milliliters, syringe units, and products supplied at different concentrations.
One additional point matters for retatrutide specifically: as of September 2026, retatrutide remains investigational. FDA states that retatrutide cannot legally be used in compounding under federal law, and Lilly says genuine retatrutide is currently available only through its clinical trials.
The concentration math discussed here is therefore best understood as general pharmaceutical and peptide science rather than instructions for preparing injectable retatrutide.
What Does Peptide Concentration Mean?
Concentration tells researchers how much of a substance exists within a defined quantity of solution.
For injectable peptide solutions, a common expression is:
mg/mL
meaning:
milligrams of peptide per milliliter of solution.
If a vial is labeled:
10 mg/mL
each milliliter contains 10 mg of the specified material.
Half a milliliter contains 5 mg.
A quarter milliliter contains 2.5 mg.
And 0.20 mL contains 2 mg.
The underlying arithmetic is simple.
What makes real medication use more complicated is that several different units are often shown at once.
A label might contain:
- milligrams
- milligrams per milliliter
- total milligrams per vial
- total vial volume
- milliliters
- syringe “units”
Those numbers describe related but different things.
Mass, Volume, and Concentration Are Different Measurements
The easiest way to understand concentration is to separate three concepts.
Mass
Mass describes how much peptide is present.
Typical units include:
mg, or milligrams
and
mcg, or micrograms.
For example:
2 mg retatrutide
would describe mass.
Volume
Volume describes how much liquid is present.
Common units include:
mL, or milliliters.
For example:
0.20 mL
describes liquid volume.
Concentration
Concentration connects the two.
For example:
10 mg/mL
means each 1 mL contains 10 mg of material.
The fundamental equation is:
Concentration = mass ÷ volume
Or rearranged:
Mass = concentration × volume
That second version is often the most useful for understanding what a given syringe volume contains.
A 10 mg/mL Example
Suppose a solution has a labeled concentration of:
10 mg/mL
A full milliliter contains:
10 mg
A half milliliter contains:
5 mg
A quarter milliliter contains:
2.5 mg
And:
0.20 mL × 10 mg/mL = 2 mg
This is the calculation behind saying that 20 U-100 syringe units of a 10 mg/mL solution correspond to 2 mg of the dissolved material.
But change the concentration and the dose changes even if the syringe is filled to exactly the same line.
What Do “Syringe Units” Actually Mean?
This is one of the most common sources of confusion.
A U-100 insulin syringe is designed for insulin at a concentration of 100 insulin units per milliliter.
As a result, the markings have a fixed relationship to volume:
| U-100 Syringe Marking | Liquid Volume |
|---|---|
| 5 units | 0.05 mL |
| 10 units | 0.10 mL |
| 20 units | 0.20 mL |
| 25 units | 0.25 mL |
| 30 units | 0.30 mL |
| 40 units | 0.40 mL |
| 50 units | 0.50 mL |
| 75 units | 0.75 mL |
| 100 units | 1.00 mL |
For a non-insulin drug, calling those markings “units” can be misleading.
The syringe is really showing a convenient scale corresponding to volume.
FDA has specifically warned that compounded GLP-1 products sometimes instruct patients to measure medication in “units,” even though the actual drug dose is prescribed in milligrams and the concentration may differ between pharmacies or even between preparations from the same compounder.
Twenty Syringe Units Does Not Mean Twenty Milligrams
This distinction is worth making explicit.
On a U-100 syringe:
20 units = 0.20 mL
It does not mean:
20 mg.
And it does not automatically mean:
2 mg.
The milligram amount depends on concentration.
Consider the same 20-unit syringe volume across several hypothetical concentrations:
| Concentration | Volume at 20 U-100 Units | Amount Present |
|---|---|---|
| 2.5 mg/mL | 0.20 mL | 0.5 mg |
| 5 mg/mL | 0.20 mL | 1 mg |
| 10 mg/mL | 0.20 mL | 2 mg |
| 15 mg/mL | 0.20 mL | 3 mg |
| 20 mg/mL | 0.20 mL | 4 mg |
The syringe position never changes.
The drug amount changes fourfold between 5 and 20 mg/mL.
That is why “I take 20 units” is incomplete information.
The Same Milligram Dose Can Also Require Different Syringe Volumes
The relationship works in the opposite direction too.
Suppose the target amount were hypothetically 2 mg.
At:
5 mg/mL, 2 mg occupies 0.40 mL.
At:
10 mg/mL, 2 mg occupies 0.20 mL.
At:
20 mg/mL, 2 mg occupies 0.10 mL.
The amount of peptide is identical.
Only the concentration and volume have changed.
This is one reason medication instructions become dangerous when people copy another person’s syringe markings without confirming that both products have the same labeled concentration.
Why Concentration Exists in the First Place
Why not simply put one dose into one vial?
Sometimes pharmaceutical manufacturers do exactly that.
Single-dose pens and prefilled syringes remove much of the calculation burden because the manufacturer controls both concentration and delivered volume.
Multi-dose vials create more flexibility.
One vial can contain several doses, and different quantities can theoretically be withdrawn.
But this means the person preparing or administering the medication has to understand the relationship among:
dose, concentration, and volume.
FDA’s compounded-semiglutide alert demonstrates the downside. Patients and even health professionals made errors when converting prescribed milligrams into syringe markings from products supplied at varying concentrations.
How Is a Pharmaceutical Concentration Chosen?
Concentration is not normally chosen arbitrarily.
Formulation scientists consider several factors.
The Required Dose
A useful concentration should allow the intended drug amount to be delivered in a practical volume.
If concentration is extremely low, the injection volume may become unnecessarily large.
If concentration is extremely high, very small measurement errors can represent larger drug errors.
Solubility
A peptide has to remain soluble at the desired concentration.
Increasing concentration can promote:
- self-association
- aggregation
- precipitation
- viscosity changes
depending on the molecule and formulation.
Chemical Stability
Peptides can undergo:
- oxidation
- deamidation
- hydrolysis
- isomerization
- other degradation reactions.
Concentration, pH, buffer composition, temperature, and excipients can influence those reactions.
Physical Stability
A peptide solution also needs to remain physically stable.
Researchers may examine:
- aggregation
- particles
- adsorption to surfaces
- fibril formation.
Delivery Device
The formulation has to work with its syringe, pen, vial, needle, or other delivery system.
A concentration appropriate for one device may not be ideal for another.
What Is Pharmaceutical Compounding?
The word compound can create another terminology problem.
In chemistry, a compound simply means a chemical substance.
But pharmaceutical compounding refers to preparing a medication to meet a particular need.
USP <797>, which governs sterile compounding standards, defines sterile compounding broadly to include activities such as combining, admixing, diluting, pooling, reconstituting, repackaging, or otherwise altering a drug or bulk drug substance to create a sterile preparation.
This is much more than mixing powder and liquid.
Sterile compounding has to control risks including:
- microbial contamination
- bacterial endotoxins
- incorrect drug strength
- chemical contamination
- physical contamination
- inappropriate ingredient quality.
USP specifically warns that poorly prepared sterile compounded products can be sub-potent, super-potent, or contaminated.
Compounding and Reconstitution Are Not Always the Same Thing
These terms are often used loosely online, but there is an important distinction.
Imagine an FDA-approved medication supplied as a dry powder with manufacturer instructions saying to add a specified diluent before administration.
Preparing that medication exactly according to its approved labeling for an individual patient is generally treated differently from creating a new compounded formulation.
USP’s sterile-compounding framework specifically notes that preparation of a conventionally manufactured sterile drug according to its approved manufacturer labeling is not considered compounding under the same circumstances described by the standard.
By contrast, taking a bulk peptide substance and creating a new injectable formulation involves a much broader compounding and quality-control problem.
The existence of simple concentration math does not make those processes equivalent.
Conceptually, How Is Concentration Created?
At a purely mathematical level, concentration depends on the amount of material and the final volume.
For example, if a professionally prepared formulation contains:
10 mg of active substance in a final volume of 1 mL
then:
10 mg ÷ 1 mL = 10 mg/mL
If the same 10 mg exists in a final volume of 2 mL:
10 mg ÷ 2 mL = 5 mg/mL
The total mass has not changed.
The material has simply been distributed through twice as much liquid.
Likewise, 20 mg in a final volume of 2 mL is again:
10 mg/mL.
This relationship is universal concentration mathematics.
It should not be mistaken for a sterile compounding recipe. Actual injectable preparation involves ingredient quality, aseptic technique, formulation compatibility, sterility assurance, endotoxin controls, labeling, and stability requirements beyond the arithmetic.
Why “Final Volume” Matters
Technically, concentration is based on the final amount of solution, not simply the nominal volume of liquid added.
In professional formulation work, scientists care about:
final concentration
and
final volume.
This matters because adding a substance to a liquid can sometimes change total volume.
For many simple educational peptide calculations, people treat the change as negligible.
Pharmaceutical manufacturing does not rely on casual assumptions when precise strength matters.
The concentration stated on a finished product is based on the validated formulation and manufacturing process.
What Is Strength?
Medication labels may use strength in several ways.
For example:
5 mg/mL
or:
10 mg/2 mL
Both can describe concentration information.
The second label means:
10 mg total in a 2 mL container,
which is equivalent to:
5 mg/mL.
FDA has warned that inconsistent ways of expressing injectable strength can contribute to medication errors. For small-volume injectable products, FDA recommends prominently expressing the total amount per total volume and also providing the amount per milliliter.
So a good label might effectively communicate both:
10 mg/2 mL
and
5 mg/mL.
That tells the reader both how much drug is in the entire container and how concentrated the solution is.
Why Compounded Products Can Be More Confusing
FDA-approved injectable products generally use a defined formulation, concentration, device, and labeling system.
Compounded products can vary.
FDA has specifically observed compounded semaglutide sold in:
- multi-dose vials
- prefilled syringes
- different concentrations.
The agency noted that even a single compounder may offer more than one concentration.
That makes this statement especially dangerous:
“Twenty units is my dose.”
Twenty units from one vial may contain twice or four times as much medication as 20 units from another vial.
FDA Has Documented Real Five- to Twenty-Fold Errors
This is not just a theoretical concern.
FDA reviewed adverse-event reports involving compounded injectable semaglutide and found patients who accidentally administered five to 20 times their intended dose.
In several cases, users were supposed to draw 5 syringe units but instead drew 50.
In another group of cases, a provider prescribed 20 units instead of 2 units, resulting in a tenfold error.
FDA reported resulting symptoms and complications including:
- nausea
- vomiting
- abdominal pain
- dehydration
- fainting
- pancreatitis
- gallstones.
Some patients required hospitalization.
The arithmetic itself was not difficult.
The system for communicating the dose was.
Why Milligrams Are Usually the More Important Drug-Dose Unit
When discussing a peptide pharmacologically, the mass of active ingredient is usually more meaningful than the syringe marking.
For example:
2 mg
describes the amount of drug.
By contrast:
20 syringe units
describes only a volume when using a U-100 syringe.
That volume becomes pharmacologically meaningful only when combined with concentration.
This is why scientific papers report peptide doses in units such as:
- mg
- mg/kg
- nmol/kg
- μg/kg
rather than saying experimental animals received “20 syringe units.”
The syringe is the delivery tool.
It is not the drug dose.
Molar Concentration Is Another Way Researchers Describe Peptides
Laboratory scientists often use molar concentration rather than mg/mL.
You may see:
- M
- mM
- μM
- nM.
These express the number of molecules rather than their mass.
For example, receptor studies may report an EC50 of:
0.5 nM
rather than mg/mL.
Converting between mass concentration and molar concentration requires knowing the peptide’s molecular weight.
The relationship is:
moles = mass ÷ molecular weight
This is useful because two different peptides can each be present at 1 mg/mL while containing different numbers of molecules if their molecular weights differ.
For pharmacological receptor experiments, molar concentration is often the more informative comparison.
Concentration Does Not Tell You Purity
Another easy mistake is assuming:
10 mg/mL concentration = 10 mg/mL pure peptide.
That depends on how drug content was determined.
A bulk peptide material can contain:
- water
- counterions
- salts
- residual solvents
- peptide-related impurities.
For pharmaceutical manufacturing, the amount of active ingredient has to be properly characterized and controlled.
This is why the concentration printed on a validated finished drug product has a different meaning from someone simply weighing nominal peptide powder and dividing by liquid volume.
Chemical purity, peptide content, and formulation concentration are related measurements.
They are not identical.
Concentration Does Not Establish Sterility Either
A perfectly calculated 10 mg/mL solution could still be microbiologically unsafe.
Sterility is an independent property.
For injectable compounded products, USP <797> exists specifically because contamination can cause severe infection or death. The chapter addresses personnel, environment, aseptic technique, component selection, quality controls, and other requirements for compounded sterile preparations.
This is why concentration calculations should not be confused with injectable preparation.
Correct arithmetic solves only one small part of the problem.
The Retatrutide Compounding Issue Is Especially Important
Retatrutide provides a useful case study because the terminology online can be misleading.
Someone may encounter products advertised as:
- compounded retatrutide
- research retatrutide
- retatrutide 10 mg/mL
- retatrutide multi-dose vial.
But FDA’s current position is explicit: retatrutide cannot be used in compounding under federal law. FDA also notes that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Lilly likewise states that retatrutide remains investigational, is not approved by any regulatory agency, and is legally available only through Lilly clinical trials.
So a vial sold online as “compounded retatrutide” should not be understood as the retatrutide equivalent of a conventional FDA-approved pharmacy product.
“Research Use Only” Does Not Fix the Problem
FDA has also warned about products containing semaglutide, tirzepatide, or retatrutide that were labeled:
for research purposes
or:
not for human consumption
while being sold directly to consumers with human-use instructions.
FDA advises consumers not to purchase these products because their quality may be unknown and they may be harmful.
The concentration printed on such a vial is only as trustworthy as the manufacturing and analytical system behind it.
If the actual concentration is different from the label, perfect syringe arithmetic will still produce the wrong dose.
Concentration Accuracy Has to Be Verified
In professional pharmaceutical manufacturing or compounding, concentration is not ideally established simply by assuming that the correct amount was added.
Quality systems may use analytical testing or validated gravimetric and volumetric processes to ensure that the preparation contains the intended strength.
Depending on the product and setting, quality control can involve:
- ingredient verification
- balance calibration
- volumetric controls
- process checks
- analytical assays
- sterility controls
- endotoxin testing
- visual inspection
- labeling verification.
USP identifies incorrect intended strength as one of the hazards sterile-compounding standards are intended to prevent.
A Better Way to Read a Peptide Vial Label
When evaluating a legitimate laboratory or pharmaceutical preparation, separate the label into distinct questions.
What Is the Total Amount?
For example:
20 mg total
What Is the Total Volume?
For example:
2 mL
What Is the Concentration?
In that example:
10 mg/mL
What Is the Intended Drug Amount?
That would be expressed in milligrams or another mass/molar unit.
What Volume Corresponds to That Amount?
That depends on concentration.
What Syringe Is Being Used?
A U-100 syringe has a different labeling system from a conventional 1 mL syringe marked directly in milliliters.
This structured approach prevents “units” from becoming a substitute for understanding the actual medication strength.
Why Copying Someone Else’s Syringe Number Is Risky
Imagine two people both say:
“I use 20 units.”
Person A has:
5 mg/mL
Person B has:
20 mg/mL
Both draw exactly 20 markings on a U-100 syringe.
Person A has 1 mg of drug.
Person B has 4 mg.
The same visual amount in the syringe contains four times as much drug.
This is exactly why a syringe marking without concentration is incomplete information.
FDA’s semaglutide warning strongly reinforces that point: variable concentrations combined with unfamiliar syringe measurement contributed to real overdose events.
A Simple Concentration Checklist
When trying to understand an injectable peptide label, the important information is:
- What is the active ingredient?
- How many total milligrams are present?
- What is the total solution volume?
- What is the resulting mg/mL concentration?
- What volume is being measured?
- What type of syringe or device is used?
- Are the instructions written in mg, mL, or syringe units?
- Has the actual concentration been professionally verified?
If any of those pieces are unclear, converting a syringe marking into a peptide dose becomes unreliable.
The Main Principle Is Simple
The mathematics of peptide concentration is straightforward:
milligrams tell you how much drug is present.
milliliters tell you how much liquid is present.
mg/mL tells you how much drug is present in each milliliter.
And on a U-100 syringe:
100 syringe markings correspond to 1 mL.
Everything else follows from those relationships.
The harder part is ensuring that the concentration on the label is real, the preparation was produced appropriately, and the person using the information has not confused syringe markings with milligrams.
FDA’s experience with compounded GLP-1 products shows that this distinction is not academic. Confusion about concentration and units has already produced substantial overdoses and hospitalizations.
For retatrutide specifically, there is an additional boundary: the molecule remains investigational, and FDA currently says it cannot legally be compounded.
So the useful scientific lesson is not how to make a particular retatrutide vial.
It is how to read concentration correctly and understand why a number such as “20 units” is meaningless without the mg/mL value behind it.
FAQs
What does 10 mg/mL mean?
It means that each milliliter of solution contains 10 milligrams of the specified drug or material.
What are 20 units on a U-100 syringe?
Twenty markings on a U-100 syringe correspond to 0.20 mL of liquid.
How many milligrams are in 20 syringe units?
It depends on concentration. At 10 mg/mL, 20 U-100 units or 0.20 mL contain 2 mg. At 5 mg/mL they contain 1 mg, and at 20 mg/mL they contain 4 mg.
Are syringe units the same as milligrams?
No. Syringe units are markings tied to volume on an insulin syringe. Milligrams measure drug mass.
Why do compounded products sometimes have different unit instructions?
Compounders may prepare different concentrations and containers. FDA has warned that this variability, combined with conversion between milligrams, milliliters, and syringe units, can contribute to medication errors.
Is reconstitution the same as compounding?
Not always. Preparing a conventionally manufactured sterile product according to its FDA-approved manufacturer instructions for an individual patient can fall outside the USP definition of compounding in that context. Creating a new sterile formulation from bulk ingredients is a different process.
Is compounded retatrutide legal?
FDA currently states that retatrutide cannot be used in compounding under federal law. Retatrutide remains investigational and is not FDA approved.
Why is concentration important for peptide research?
Researchers need an accurate concentration to interpret dose-response relationships, receptor potency, toxicity, stability, and other quantitative results. If the actual concentration differs from the assumed concentration, the experimental conclusions can also be wrong.
References
U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated With Compounded Injectable Semaglutide Products. The FDA documents confusion among milligrams, milliliters, syringe units, and variable compounded concentrations, including five- to twentyfold dosing errors. FDA compounded semaglutide dosing-error alert
U.S. Food and Drug Administration. FDA’s Concerns With Unapproved GLP-1 Drugs Used for Weight Loss. Includes current FDA information on compounded GLP-1 products and the agency’s statement that retatrutide cannot be used in compounding under federal law. FDA guidance on unapproved GLP-1 drugs and retatrutide
United States Pharmacopeia. USP General Chapter <797>: Pharmaceutical Compounding—Sterile Preparations. Describes sterile compounding and minimum standards intended to reduce contamination and dosing risks. USP General Chapter 797 overview
U.S. Food and Drug Administration. Differences in Strength Expression on Product Labels of Compounders and Conventional Manufacturers May Lead to Dosing Errors. Discusses strength-expression practices for small-volume injectable products. FDA guidance on injectable strength labeling
Eli Lilly and Company. What to Know About Retatrutide. Updated July 2026. Lilly states that retatrutide remains investigational and is currently available only through its clinical trials. Lilly retatrutide research overview